They were supposed to be miracle injections: weekly shots that could tame type 2 diabetes and melt away stubborn kilograms with remarkable ease. But for growing numbers of patients around the world, the promise of Ozempic, Wegovy, Mounjaro and Zepbound has been replaced by fear — fear that the pen in their hand is fake, contaminated or completely useless.
A sophisticated global black market, fuelled largely by raw pharmaceutical ingredients from China, is flooding countries with counterfeit and substandard versions of these blockbuster GLP-1 drugs. What began as a medical breakthrough has become a public health headache stretching from boardrooms in Beijing to residential flats in India, online pharmacies in the United States and back-street operations in Europe.
The China pipeline
At the heart of the problem is China’s vast pharmaceutical manufacturing base. Investigative journalists and regulators have repeatedly traced suspect supplies back to Chinese suppliers offering active pharmaceutical ingredients (APIs) — the raw powder form of semaglutide or tirzepatide — often labelled “for research use only” or sold with minimal questions asked.
In one striking case uncovered by CNBC in 2024, undercover reporters ordered what was advertised as Ozempic online. The package arrived from an office building in Shijiazhuang, a major pharmaceutical centre in northern China. Testing and manufacturer confirmation showed it was diverted legitimate product, not intended for the market where it ended up. Similar shipments continue to surface.
US data tells a sobering story. Between September 2023 and January 2025, American customs officials recorded at least 239 suspicious shipments of semaglutide and tirzepatide raw materials from unregistered manufacturers. Sixty of them came from China or Hong Kong. Most slipped through. In January 2026, a US congressman formally challenged three Chinese biotech companies to explain how their GLP-1 ingredients were ending up in unauthorised products abroad.
A problem that respects no borders
The consequences are appearing everywhere. In Britain, the Medicines and Healthcare products Regulatory Agency has seized thousands of fake or unlicensed GLP-1 injections. Some contained insulin instead of the intended drug — a potentially lethal swap. Others were filled with bacteria or simply water.
The World Health Organization has issued repeated global alerts about falsified semaglutide, with confirmed counterfeits found in Brazil, the United States, the United Kingdom and several other countries. Patients have reported infections, abscesses, uncontrolled blood sugar and, in at least one documented case, death linked to suspected fake versions.
Even in India, where genuine supplies are expensive and often scarce, authorities recently raided a flat in Gurugram where raw tirzepatide imported from China was being mixed with water and packaged as Mounjaro in a residential kitchen.
Patients desperate for the drugs — which can produce 15 per cent or more weight loss — are particularly vulnerable. Genuine pens can cost hundreds of pounds or dollars a month and have faced chronic shortages. That gap has been eagerly filled by online sellers, social media advertisements and shady compounding operations promising the same results at a fraction of the price.
The human cost
The stories are troubling. Patients have described injecting what they believed was authentic medicine only to develop painful swellings at the injection site or see no improvement in their condition after weeks of use. Doctors report increasing numbers of people arriving in clinics with complications from counterfeit products, including serious infections caused by non-sterile manufacturing.
For many, the appeal is not merely medical. Social media has turned these injections into a lifestyle product, fuelling demand that legitimate supply chains simply cannot meet.
The fightback
Drug makers Novo Nordisk and Eli Lilly have launched aggressive legal campaigns against counterfeiters and unauthorised compounders. Regulators in the US, UK and Europe have stepped up border checks, issued public warnings and restricted large-scale compounding of these drugs. The FDA has placed certain Chinese manufacturers on import alerts.
Yet officials admit the challenge is immense. Online sales, international mail shipments and B2B platforms move faster than enforcement can track. As long as shortages persist and prices remain high, the shadow market is likely to thrive.
A warning to patients
Health authorities worldwide offer the same clear advice: buy these medicines only from licensed pharmacies with a valid prescription. Check packaging carefully for proper batch numbers, holograms and tamper-evident seals. If a deal seems too good to be true, it almost certainly is.
The rise of these powerful weight-loss drugs represents one of the most significant medical advances in decades. But their success has also exposed dangerous weaknesses in the global pharmaceutical supply chain. Until supply catches up with demand and regulators close the loopholes, patients will continue to face a stark choice: wait for the real thing, or risk their health with a fake.
The counterfeit trade in GLP-1 drugs is no longer a niche criminal problem. It is a worldwide public health threat born from hope, greed and regulatory lag — and it shows little sign of disappearing soon.
